StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.15+0.03 (+2.68%)

Close on Nov 18, 2026Market cap $5.00MP/E –Yield –

BioLineRx gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was $950.00K, down 95.2% from the year before. The highest annual figure on record is $19.68M in fiscal 2024.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$950.00K-95.2%
FY2024Dec 31, 2024$19.68M+1675.9%
FY2023Dec 31, 2023$1.11M–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$235.00K–
Q2 FY2025Jun 30, 2025$232.00K–
Q2 FY2024Jun 30, 2024$4.50M–
Q2 FY2023Jun 30, 2023$0–

More BioLineRx figures

See a number that looks wrong?